Production (Stage)
Atea Pharmaceuticals, Inc.
AVIR
$2.90
$0.051.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 68.48M | 71.03M | 66.46M | 64.59M | 57.52M |
| Gross Profit | -68.48M | -71.03M | -66.46M | -64.59M | -57.52M |
| SG&A Expenses | 46.08M | 48.85M | 47.02M | 48.58M | 49.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 140.70M | 171.47M | 165.07M | 164.77M | 158.65M |
| Operating Income | -140.70M | -171.47M | -165.07M | -164.77M | -158.65M |
| Income Before Tax | -138.59M | -167.46M | -172.96M | -174.95M | -162.61M |
| Income Tax Expenses | 897.00K | 925.00K | 1.05M | 1.04M | 1.05M |
| Earnings from Continuing Operations | -139.49 | -168.39 | -174.01 | -176.00 | -163.66 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -139.49M | -168.39M | -174.01M | -176.00M | -163.66M |
| EBIT | -140.70M | -171.47M | -165.07M | -164.77M | -158.65M |
| EBITDA | -140.29M | -171.05M | -164.66M | -164.35M | -158.23M |
| EPS Basic | -1.65 | -2.00 | -2.07 | -2.10 | -1.96 |
| Normalized Basic EPS | -0.87 | -1.08 | -1.02 | -1.01 | -0.96 |
| EPS Diluted | -1.65 | -2.00 | -2.07 | -2.10 | -1.96 |
| Normalized Diluted EPS | -0.87 | -1.08 | -1.02 | -1.01 | -0.96 |
| Average Basic Shares Outstanding | 338.30M | 337.06M | 336.03M | 335.01M | 334.15M |
| Average Diluted Shares Outstanding | 338.30M | 337.06M | 336.03M | 335.01M | 334.15M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |